Chinese Journal of Pharmacovigilance ›› 2025, Vol. 22 ›› Issue (4): 472-474.
DOI: 10.19803/j.1672-8629.20240510

Previous Articles     Next Articles

One Case of Rash Caused by Apalutamide Combined with Goserelin

ZENG Ji1, ZHANG Jinke2, WANG Li2, CHEN Jun3, MENG Xudong4, NING Jing5, HUANG Cheng6   

  1. 1Department of Pharmacy, Ma’anshan Hospital of Traditional Chinese Medicine Affiliated to Anhui University of Traditional Chinese Medicine, Ma’anshan Anhui 243000, China;
    2Department of Oncology, Ma’anshan Hospital of Traditional Chinese Medicine Affiliated to Anhui University of Traditional Chinese Medicine, Ma’anshan Anhui 243000, China;
    3Department of Emergency, Ma’anshan People’s Hospital, Ma’anshan Anhui 243000, China;
    4Department of General Surgery, Ma’anshan People’s Hospital, Ma’anshan Anhui 243000, China;
    5Department of Dermatology, the Third Affiliated Hospital of Soochow University, Changzhou Jiangsu 213000, China;
    6Laboratory of Inflammation and Immune-Mediated Diseases, Anhui Provincial Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei Anhui 230032, China
  • Received:2024-07-26 Published:2025-04-17

PDF (PC)

61

Abstract: Objective To investigate a case of drug-induced rash during treatment with apalutamide tablets combined with goserelin acetate sustained-release implant in order to provide data for safe and rational medications. Methods After analysis of one case of rash caused by the combined use of apalutamide tablets and goserelin acetate sustained-release implant, an individualized plan for pharmacotherapeutic monitoring was developed based on related literature and clinical experience. Additionally, recommendations for new medications were provided. Results In-depth analysis of the patient’s medication history, prescriptions and relevant literature identified apalutamide tablets and goserelin acetate sustained-release implant as the suspected cause of the adverse reaction. Apalutamide was promptly discontinued, and antihistamine therapy was initiated. Concurrently, the statin regimen was adjusted to mitigate potential drug interactions, with close monitoring of lipid profiles. The patient’s systemic rash and pruritus showed marked improvement within about three weeks. Conclusion Potential rash-related adverse reactions may occur when apalutamide is administered in combination with goserelin acetate sustained-release implants. Quick regimen adjustments and proactive monitoring are critical to medication compliance and patient safety.

Key words: Apalutamide, Goserelin, Rash, Itching, Adverse Drug Reaction

CLC Number: